JANX · Janux Therapeutics, Inc.
$17.28
-0.24 (-1.37%)
At close · Aug 20
Market Cap
$1.07B
Shares
61.14M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.28
Open$17.29
Day$17.19–17.64
52W close$12.18–34.74
Avg vol 30d733K
Short int5.9M · 9.7% float · 7.7d
Short vol67%
Last earningsDec 1, 2025
DataJun 2021–Aug 2026
Filing10-Q · Aug 6
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+7%
above
Price vs 50-day avg
+11%
above
RSI (14)
63
neutral
MACD trend
Positive
52-week position
23%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+10%
trailing
6-month return
+27%
trailing
YTD return
+25%
this year
Relative strength
+16%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $16 › 200d $16 — 200d above 50d
Institutional flow
Accumulating
+3% holders QoQ · +40 funds added
Insider flow
Distributing
Net -$56.9K over 90 days · 100% sells
Short interest
Falling
9.69% of float · ▼ -8.2% MoM · 7.7 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
198 holders — mid 3-yr range
Squeeze score
67
elevated · 0–100
Fundamentals
Revenue growth
−6%
Y/Y
EPS growth
−43%
Y/Y
Free cash flow
$-83.3M
Balance sheet
$52.3M
net cash
Quant / Vol
risk profile
Volatility
73%
annualized · 1-yr
Max drawdown
−65%
past year
ATR
3.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+7%
Bullish
Price vs 50-day avg
+11%
Bullish
RSI (14)
63
Neutral
MACD trend
Positive
Bullish
52-week position
23%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $16 › 200d $16 — 200d above 50d
Institutional flow
Accumulating
+3% holders QoQ · +40 funds added
Insider flow
Distributing
Net -$56.9K over 90 days · 100% sells
Short interest
Falling
9.69% of float · ▼ -8.2% MoM · 7.7 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
198 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $12
Now $17 · 23%
Range high $35
vs 200-day avg +7%
vs 50-day avg +11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JANX
this stock
Janux Therapeutics, Inc.
|
$1.07B | +25.2% | -5.6% | — | 9.7% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JANX | +8.0% | +9.9% | +27.0% | +13.9% | +25.2% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +10.0% | +6.6% | +15.8% | +11.8% | +13.4% |